dpp 4 inhibitor glp 1 agonist Glucagon-like peptide-1 The Impact of Dipeptidyl-peptidase 4
Description
Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, et al
New York: Medscape
N Engl J Med 2001;345:851-60.ArticlePubMed 10
However, a lower rate of cardiovascular death and heart failure hospitalizations was seen [24]
Derek Thompson: How long did it take Lilly to recognize that what had begun as a type 2 diabetes drug was in fact an incredibly powerful weight-loss drug
Furthermore, a real-world retrospective study comparing the compliance of patients receiving different GLP-1RAs for the treatment of hyperglycemic found that even if GLP-1RA weekly preparations were used, there were still differences in compliance [171]
